search
HER2
Trends
- 1EU Approves T-DXd for Residual HER2-Positive Early Breast Cancer▼T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
The European Union has approved trastuzumab deruxtecan (T-DXd) for patients with residual HER2-positive early breast cancer, expanding access to the antibody-drug conjugate beyond its existing metastatic indications. The decision follows positive trial results showing improved outcomes for patients with remaining disease after neoadjuvant therapy. Oncologists have welcomed the approval as a meaningful new treatment option in the curative-intent setting.
- 2NRG1 fusions and HER2 overexpression: same pathway, distinct biology▼NRG1 fusion vs HER2 overexpression: A shared pathway but distinct biology
Oncology discussions are contrasting NRG1 gene fusions with HER2 overexpression, two cancer drivers that activate the same ErbB signaling pathway but behave as biologically distinct entities. The comparison highlights that despite shared downstream signaling, the two alterations differ in their underlying biology, which has implications for how tumors are classified and how targeted therapies are selected for patients carrying each alteration.
- 3Bispecific ADC doubles progression-free survival in breast cancer●ESMO26: An $8.4bn bispecific ADC doubles PFS in HR+/HER2- breast cancer
Data presented at the ESMO 2026 congress show an $8.4 billion bispecific antibody-drug conjugate doubled progression-free survival in patients with HR-positive, HER2-negative breast cancer. The results point to a significant advance for a common cancer subtype with limited options after endocrine therapy resistance, and are drawing attention from oncologists and investors alike given the drug's commercial potential.